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performed in a primary and secondary healthcare 
center and it possibly indicates the colonization rate of 
the community. 
This first VRE clinical isolate of the VanB pheno- 
type is probably the tip of the vancomycin resistance 
'iceberg' in our hospital. It indlcates a possible need for 
adjustments in the testing of vancomycin resistance 
and in VRE carriage surveillance in all tertiary-care 
institutions, since the transfer of seriously ill patients 
h m  one hospital to another is common practice. 
Clinical laboratories must adopt a sensitivity testing 
method that is able to recognize the VanB phenotype, 
and should also apply a surveillance program for VRE 
based on the agar-screening test. They must also try to 
reinforce the infection control policies, to reduce the 
risk of nosocomial transmission of VRE. 
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The diagnosis of tuberculosis is well known as being a 
slow process, particularly in extrapulmonary cases. In 
these clinical presentations, the Ziehl-Neelsen stain for 
acid-fast bacilli in smears tends to be negative, making 
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it necessary to wait for culture of the bacteria, which 
typically takes at least 2 weeks, in order to confirm the 
diagnosis [l]. The use of DNA amplification methods 
for the detection of Mycobacter-ium tuberculosis in respira- 
tory samples has yielded encouraging results, even in 
children [24], but there is little reported experience 
with clinical samples other than sputum. 
The LCx MTB system h m  Abbott Diagnostic, 
Chicago, Il, USA, is based on the ligase chain reaction 
to detect DNA and has already been used to i d e e  
various microorganisms, including M. tuberculosis, h m  
sputum [7-10]. The amplified hgment corresponds to 
the gene encoding the b antigen (38-kDa protein), 
specific for M. tuberculosis [ll]. We set out to evaluate 
the ability of the LCx MTB system to detect M. 
tuberculosis in clinical samples other than sputum. 
Three hundred and fifty-eight non-respiratory 
clinical samples were submitted consecutively for extra- 
pulmonary tuberculosis diagnosis and were included in 
the study without any exclusion criteria other than the 
minimum quantity necessary for processing. AD samples 
were processed on the day of arrival at the laboratory. 
They were decontaminated with N-acetylcysteine- 
NaOH [12], and smears were stained with the Ziehl- 
Neelsen stain. In all cases, 0.2 mL of the centrifuged 
concentrate was seeded on Lowenstein-Jensen (LJ) 
agar, and 0.5d was inoculated into MGIT liquid 
medium (Becton Dickinson, Cockeysville, Ma, USA). 
The remaining pellet was kept at -2OOC until tested in 
the LCx MTB assay according to the manufacturer’s 
instructions for respiratory samples, as there were no 
specific protocols for other types of specimen. Both 
positive and negative controls were used in each diag- 
nostic session. 
A diagnosis of tuberculosis was reached when at 
least one laboratory test, other than staining, was 
positive. In cases where test results conflicted, the 
histopathologic findings of typical granuloma and/or 
presence of caseous necrosis, and the response to 
treatment, were taken into consideration. 
Of the 358 samples studied, 28 (7.8%) were 
positive in the amplification assay and 20 were culture 
confirmed. The remaining eight specimens were either 
culture negative (n=7) or contaminated (a= 1). Overall, 
for 300 (83.8%) samples there was complete agreement 
in test results between the LCx MTB assay and culture. 
This was increased to 96.3% if samples were included 
in which the LCx MTB result agreed with one other 
technique, even if there was either contamination or 
insdlicient culture material for the third test. 
There were 13 samples that gave discrepant results. 
Four were negative in the assay but grew in both culture 
media: two of these were gastric fluids h m  the same 
patient and the third was a urine sample. The fourth 
sample was a pleural biopsy fiom a patient with pleural 
efision. The biopsy f.?agments were too small to be 
split between culture media and the assay and so were 
used for either procedure; w e  cannot be sure that both 
fi-agments were representative of the lesion. Eight 
samples positive in the assay failed to grow in culture; 
six of these were diagnosed as tuberculosis on a 
histopathologic basis and a good response to treatment. 
A urine sample was considered to give a false-positive 
reaction in the LCx MTB assay, as the patient showed 
no other signs of tuberculosis and repeated samples 
proved negative in a l l  tests. The other false-positive 
result with the LCx MTB assay was a pleural fluid 
sample h m  a patient previously diagnosed and under 
treatment for 4 months. The last sample (pleural fluid) 
failed to grow on LJ agar but grew in MGIT; two other 
pleural samples fiom this patient were positive in all 
tests. In addition, there were two cases due to atypical 
mycobacteria, and each of these was negative in the 
assay. Thus, of the 13 discrepant results, the E x  MTB 
system appeared to be correct on seven occasions, with 
two false-positive and four f&e-negative results. 
Using the criteria established earlier, 30 tuber- 
culosis samples were diagnosed, of which 26 were LCx 
MTB positive and four were false negative. Ofthe 328 
samples that did not contain M. tuberculosis, all but two 
were LCx MTB negative, with two false positives. The 
sensitivity value for the LCx MTB system was 86.6% 
(26/30) with a specificity of 99.4% (326/328). 
The 28 samples that were LCx MTB positive 
came h m  17 patients (Table 1). The types of extra- 
pulmonary tuberculosis dqnosed included five pleural, 
four ganglionar, three urinary tract, two meningitis, 
one paracostal, and a paravertebral and a retroperitoneal 
abscess. Ziehl-Neelsen sta in ing  was positive in only five 
(29.4%) of these patients, and the remaining cases 
would have required culture and a delay of several 
weeks if the amplification assay was not available. In 
summary, there were 20 tuberculosis cases, 17 of which 
were detected by the LCx MTB system. On six 
occasions, it was the only test to detect the presence of 
M. tuberculosis, and on 12 occasions, it proved to be the 
most rapid technique. 
One of the problems frequently encountered with 
the dngnosis of tuberculosis is the slow metabolism of 
M. tuberculosis, which necessitates an 8-week waiting 
period to rule out a negative culture [13]. This incon- 
venience is greater for non-respiratory samples, in 
which the number of mycobacteria may be very low 
and not detected by the screening stain. For these 
samples, a highly sensitive genetic amplification tech- 
nique would be of great value for diagnosis [4,14,15]. 
The LCx MTB assay is a s i l e  standardized system, 
and our results, even using the mand-r’s protocol 
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Table 1 Results of two culture techniques used and time taken for the detection of M. tuberculosis in 17 patients positive 
with the LCx MTB assay 
~~ ~~~~ 
Case Weeks for the 
number Patient Type of sample Ziehl-Neelsen Cultures (LJ and MGIT) most rapid culture 
1 BGG Ganghon biopsy + + 3 
2 GSC Paracostal biopsy - 
+ 6 3 CFF Pleural fluid - 
4 SBH Pleural fluid - 
+ 3 5 LB Pleural fluid - 
6 FPG CSF + 6 
7 LME Urine + + 2 
8 ASA Urine - - 
9 EDR Ganghon biopsy - - 
10 TPB Paravertebral biopsy + + 3 
11 MSC Urine + + 3 
Ganglion biopsy - - 12 DAJ 
13 NRG Retroperitoned abscess + + 2 
14 CPA CSF + 6 
15 YGR Pleural fluid - 
+ 2 16 EPM Ganglion biopsy - 
+ 2 Pleural fluid - 17 JA 
Contaminated 
- 
- 
- 
- 
CSE cerebrospinal fluid. 
for sputum with non-sputum samples, showed a 
specificity of 99.4%, which is similar to other studies 
[ 16,171. 
‘The LCx MTB system identified 17 of 20 cases of 
extrapulmonary tuberculosis, Ziehl-Neelsen staining 
detected only five patients, and cultures identified 14 
patients, three of whom were not diagnosed through 
the amplification method. One of the latter patients 
was a 4-year-old girl whose gastric fluid was sent as the 
sample. The low pH of these samples makes it necessary 
to process them quickly, and sample h a n k  may not 
have been ideal. In the second false-negative LCx MTB 
case, a pleural biopsy, the negative result could have 
been due to either an inadequate sample or the 
presence of inhibitors, as has been shown for up to 20% 
of samples [18]. The LCx MTB system cannot detect 
the presence of inhibitors in the reaction, unlike the 
Cobas Amplicor PCR, which has an internal ampli- 
fication control for each sample and facilitates the 
monitoring of inhibitory factors in the reaction [19]. 
An alternative explanation could be that the sample was 
not truly pleural, or that the heterogeneous distribution 
ofmycobacteria in the pleura resulted in a bgment fiee 
of mycobacteria being chosen for amplification [2,16, 
201. This possibility suggests that various hgments 
from distinct locations should be submitted for testing. 
Two other relevant factors emerged from our study. 
The first refers to two cases of atypical mycobacteria 
where the culture was positive and the LCx MTB assay 
was negative. This indicated the correct specificity 
in the amplification, and enabled us to diEerentiate 
between atypical and typical mycobacterial tuber- 
culosis. From a clinical point of view, cases with a 
positive smear stain and a negative amplification assay 
result should be interpreted as atypical mycobacteriosis, 
while awaiting the results of culture, a practice observed 
by other authors using the same system [9,16,20]. The 
second factor involved cases of already diagnosed and 
treated tuberculosis. In our study, one of the cases in 
which both culture methods used were negative had 
already been diagnosed with pleural tuberculosis and 
treated correctly for 4 months. The LCx MTB gave a 
probable false-positive result, since the goal of the 
system is to diagnose active tuberculosis as opposed to 
episodes. In pulmonary tuberculosis and with a large 
number of cases, this technique has been found to be 
usefid in the follow-up of antituberculosis therapy [21], 
and mycobacterial DNA has been reported even after 
treatment resulted in negative cultures [22]. These 
discrepancies make it necessary to design studies to 
clarifl whether DNA-based detection systems have a 
role in the control of the efficiency of treatment. 
Although the LCx MTB is highly sensitive, its capacity 
to detect DNA h m  non-viable bacteria and its cost 
argue against it being a good candidate for this role. 
In conclusion, this study confirms that the LCx 
MTB system can be applied to non-respiratory samples 
with a good diagnostic outcome. It is easy to use and 
the results are rapid, sensitive and specific. 
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